Related Experiment Video
Updated: Jan 17, 2026
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Adverse events of antibody-drug conjugates: comparative analysis of agents with a common payload using the adverse
Kenta Yamaoka1,2, Sho Masago2,3, Mayako Uchida4
1Department of Pharmacy, Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan.
Background:
Antibody-drug conjugates (ADCs) have been implicated in myelosuppression and peripheral neuropathy (PN), possibly owing to their payload. Thus, their systemic toxicity should be considered. However, reports documenting adverse event (AE) occurrences in clinical settings are limited. This study analyzed AEs associated with polatuzumab vedotin, brentuximab vedotin, and enfortumab vedotin-which share a common payload-based on patient background factors using Japanese and United States AE spontaneous reporting databases.
Materials And Methods:
This study examined data from the Japanese Adverse Drug Event Report database (April 2004-June 2023) and the Food and Drug Administration AE Reporting System (first quarter of 1997-third quarter of 2023). Safety signals for an AEs were defined as a reporting odds ratio lower limit of the 95% confidence interval >1. Additionally, AEs were stratified based on sex, age, and body mass index to explore correlations between patient demographics and AEs.
Results:
Signals of PN, myelosuppression, and febrile neutropenia were detected in all ADCs. Polatuzumab vedotin showed earlier PN onset than other drugs and rare AEs such as heart failure. Enfortumab vedotin had widely detected skin-related AEs. Stratified analysis showed more AEs in males aged ≥60 years.
Conclusions:
Our study identifies common AEs, including PN and myelosuppression in ADCs sharing the same payload. Onset duration and outcomes of each AE vary among ADCs.
More Related Videos
11:58Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
05:21Author Spotlight: Optimizing Antibody-Based Cancer Treatments via Antibody-Dependent, Cell-Mediated Cytotoxicity Assay
Published on: September 13, 2024
Related Concept Videos
01:19Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...